J&J Urges Switch To Sun's Doxil Generic If U.S. Supplies Run Out
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson has taken the unusual step of advising patients no longer with access to its Doxil (doxorubicin) cancer drug to switch to the Sun Pharmaceutical Industries generic until adequate supplies resume.